Precision gene delivery remains one of the greatest challenges in modern medicine. A Basel-based biopharma company, Vector BioPharma, has accepted the challenge and, with cutting-edge technology from the University of Zürich, is developing a revolutionary new way to deliver the right genes to the right place at the right time. Vector BioPharma aims to be the pioneer in delivering future medicines with this technology, now under development in multiple areas of urgent medical need.
CatalYm GmbH raises €50m to push visugromab development
Latest NewsMunich-based immunooncology specialist CatalYm GmbH wants to use €50m from a Series C financing round to advance its anti-GDF15 antibody to Phase II development.
Cultimate Foods UG raises €700.000 in pre-seed financing
Latest NewsCellular agriculture company Cultimate Foods UG has got a pre-seed funding led by Big Idea Ventures, ProVeg International and Realum.cloud.
Cradle BV bags €5.4m in seed financing
Latest NewsBiotech start-up Cradle BV has raised €5.4m in seed financing to design cell-factories with AI and scale bioprocesses much faster and cheaper.
Vector BioPharma: the future of gene delivery
BackgroundPrecision gene delivery remains one of the greatest challenges in modern medicine. A Basel-based biopharma company, Vector BioPharma, has accepted the challenge and, with cutting-edge technology from the University of Zürich, is developing a revolutionary new way to deliver the right genes to the right place at the right time. Vector BioPharma aims to be the pioneer in delivering future medicines with this technology, now under development in multiple areas of urgent medical need.
Standing Ovation inks exlusive partnership with Bel Group
Latest NewsMicrobial casein maker Standing Ovation SA has inked an exklusive collaboration with Bel Group, one of France’s biggest cheese-makers to bring its vegan cheese to the market.
EpiEndo Pharmaceuticals pushes COPD candidate
Latest NewsEpiEndo Pharmaceuticals ehf got the green light for a Phase IIa COPD trial with its non-anbibiotic macrolide EP395
Novo Nordisk Foundation funds Plant2Food with €27m
Latest NewsDanish Novo Nordisk Foundation has invested in Plant2Food, a new open innovation hub for researchers and companies to develop plant-based foods.
OxSonics Therapeutics with new Chief Executive Officer
AppointmentsAt the beginning of november, OxSonics Therapeutics has appointed Jérôme Marzinski as its Chief Executive Officer.
Crossing the commercialisation chasm
BackgroundAs a late-stage investor focusing on the European bioeconomy, the ECBF is carefully assessing the maturity of any technology, but more important than maturity is the ability to reach commercial scale. What governs that scale-up, and how do we assess it? What role does the TRL score play, and what key questions do we ask? An excerpt into a framework.
CDMO excellence in phytocannabinoid products
BackgroundCB21 Pharma Ltd announces that it entered a global strategic collaboration to combine
its leading expertise and clinical research program in phytocannabinoids with world-class
pharmaceutical strategic consulting and business development services of NorthStar Corporate Finance Ltd and Kru?ger Beteiligungs GmbH, forming a new company called CB21 R&D.